Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Fineline Cube Aug 10, 2026
Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026
Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Fineline Cube Aug 10, 2026
Company Drug

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Fineline Cube Aug 10, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026

Curium Pharma, a private equity-backed radiopharmaceutical company, has agreed to acquire peer Lantheus Holdings (NASDAQ:...

Company Drug

Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients

Fineline Cube Aug 5, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ)‘s New...

Company Drug

Haixi Pharma’s Oral nAMD Drug Candidate HX9428 Receives FDA Clearance for Phase 2 Trials, Offering Alternative to Intravitreal Injections

Fineline Cube Aug 5, 2026

Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced that the Investigational New Drug (IND) application...

Company Drug

Sanofi Secures European Commission Approval for MenQuadfi Pediatric Indication Extension to Infants from Six Weeks of Age

Fineline Cube Aug 5, 2026

Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has approved an extension of the...

Company

Novo Nordisk Reports Q2 2026 Net Sales of DKK 78.5B, Driven by Strong Semaglutide Performance Despite Portfolio Restructuring

Fineline Cube Aug 5, 2026

Novo Nordisk (NYSE: NVO) today released its financial results for the second quarter of 2026,...

Company Drug

Alphamab Oncology’s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review

Fineline Cube Aug 5, 2026

Alphamab Oncology (HKG: 9966) announced that the New Drug Application (NDA) for Anbenitamab (trade name:...

Company

Innovent Biologics Reports H1 2026 Revenue Exceeding RMB 8.2 Billion, Up 55% Year‑Over‑Year

Fineline Cube Aug 5, 2026

Innovent Biologics (HKG: 1801) today announced its product revenue for the first half of 2026,...

Company

AbbVie Reports 10.2% Revenue Growth in Q2 2026, Driven by Strong Immunology Performance

Fineline Cube Aug 5, 2026

AbbVie (NYSE: ABBV) announced financial results for the second quarter (Q2) of 2026. Financial Performance...

Company

WuXi AppTec Reports 38.9% Revenue Growth in H1 2026, Raises Full-Year Guidance

Fineline Cube Aug 5, 2026

WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) released its first-half 2026 (H1’2026) financial results....

Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026

Alphamab Oncology (HKG: 9966) announced that it has entered into a licensing agreement with Pathos...

Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026

In May 2026, Hunan Zonsen PepLib Biotech Inc. successfully completed a Series C financing round...

Company Drug

CARsgen Therapeutics’ CT0596 Receives NMPA Clinical Approval for Relapsed/Refractory Multiple Myeloma

Fineline Cube Aug 5, 2026

CARsgen Therapeutics (HKG: 2171) announced that CT0596 has received clinical approval from the National Medical...

Company Drug

InnoCare Pharma’s Orelabrutinib-Mesutoclax Combination Receives Breakthrough Therapy Designation for Marginal Zone Lymphoma

Fineline Cube Aug 5, 2026

InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced that the combination regimen of orelabrutinib and...

Company Drug

Adlai Nortye’s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC

Fineline Cube Aug 5, 2026

Adlai Nortye (NASDAQ: ANL) announced that the company’s independently developed antibody-drug conjugate (ADC) AN4035, which...

Company Drug

Zai Lab’s Zocilurtatug Pelitecan Receives FDA Orphan Drug Designation for Neuroendocrine Carcinoma

Fineline Cube Aug 4, 2026

Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced that the US Food and Drug Administration (FDA)...

Drug

FDA Grants Biologics License to Ezplaz Freeze-Dried Plasma, First FDP Approved in United States

Fineline Cube Aug 4, 2026

On July 29, 2026, the U.S. FDA granted a biologics license to Ezplaz Freeze Dried...

Company Drug

Novartis’ Pluvicto Receives FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer

Fineline Cube Aug 4, 2026

Novartis (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has approved Pluvicto...

Company

HutchMed Reports H1 2026 Results with Strong Oncology Growth Despite Overall Revenue Decline

Fineline Cube Aug 4, 2026

HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced its financial results for the six months...

Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026

Siemens Healthineers AG (ETR: SHL) and Cleveland Clinic announced the signing of a 10-year strategic...

Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026

Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) announced that it has signed a Strategic Cooperation Framework...

Posts pagination

1 2 3 4 … 705

Recent updates

  • GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled
  • Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor
  • WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation
  • Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials
  • Grand Pharma’s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Legal / IP

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Company Drug

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.